EMMA (Emmaus Life Sciences) Interest Coverage: 0 (At Loss) (As of Mar. 2026)


What is Emmaus Life Sciences Interest Coverage?

Emmaus Life Sciences EMMA -16.67% Interest Coverage is 0 (At Loss) as of Mar. 2026. The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, Emmaus Life Sciences ranks worse than 99.47% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Emmaus Life Sciences's Operating Income for the three months ended in Mar. 2026 was $-0.82 Mil. Emmaus Life Sciences's Interest Expense for the three months ended in Mar. 2026 was $-2.13 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Emmaus Life Sciences Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.

The historical rank and industry rank for Emmaus Life Sciences's Interest Coverage or its related term are showing as below:

EMMA' s Interest Coverage Range Over the Past 10 Years
Min: 0.03   Med: 0.26   Max: 0.48
Current: 0.05

EMMA's Interest Coverage is ranked worse than
99.47% of 377 companies
in the Biotechnology industry
Industry Median: 106.07 vs EMMA: 0.05

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emmaus Life Sciences  (OTCPK:EMMA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Emmaus Life Sciences Interest Coverage Related Terms

Emmaus Life Sciences Interest Coverage Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Emmaus Life Sciences Interest Coverage Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.48 0.00 0.03

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.36 0.39 0.00

EMMA vs CERO, AGTX, WINT: Interest Coverage Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Interest Coverage falls into.


Emmaus Life Sciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emmaus Life Sciences's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Emmaus Life Sciences's Interest Expense was $-7.13 Mil. Its Operating Income was $0.23 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.68 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2025 )/Interest Expense (A: Dec. 2025 )
=-1*0.231/-7.134
=0.03

Emmaus Life Sciences's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Emmaus Life Sciences's Interest Expense was $-2.13 Mil. Its Operating Income was $-0.82 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.60 Mil.

Emmaus Life Sciences did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Emmaus Life Sciences (EMMA) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Emmaus Life Sciences and its competitors. Over the past decade, Emmaus Life Sciences' Interest Coverage has ranged from 0.03 to 0.48. According to the industry distribution chart, Emmaus Life Sciences ranks #375 out of 377 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Emmaus Life Sciences' Interest Coverage too high?
Emmaus Life Sciences' current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.48. Based on the distribution chart, Emmaus Life Sciences ranks #375 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Interest Coverage compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #375 out of 377 companies for Interest Coverage. This places Emmaus Life Sciences in the lower half of its industry. The industry median Interest Coverage is 106.07. Historically, Emmaus Life Sciences' own Interest Coverage has ranged from 0.03 to 0.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.